暫時無法取得訂價和供貨情況
推薦產品
品質等級
化驗
≥95% (HPLC)
形狀
solid
製造商／商標名
Calbiochem®
儲存條件
OK to freeze
protect from light
顏色
yellow
溶解度
DMSO: 5 mg/mL
運輸包裝
ambient
儲存溫度
2-8°C
SMILES 字串
N6(CCC(CC6)[n]7c8c(nc7O)cccc8)Cc1ccc(cc1)c2nc3c(nc2c5ccccc5)cc4[nH]cnc4c3
InChI
1S/C34H29N7O/c42-34-39-26-8-4-5-9-31(26)41(34)25-14-16-40(17-15-25)20-22-10-12-24(13-11-22)33-32(23-6-2-1-3-7-23)37-29-18-27-28(36-21-35-27)19-30(29)38-33/h1-13,18-19,21,25H,14-17,20H2,(H,35,36)(H,39,42)
InChI 密鑰
BIWGYFZAEWGBAL-UHFFFAOYSA-N
一般說明
Akt1/Akt2活性的细胞可渗透，可逆，有效和选择性抑制剂（在体外激酶测定中，Akt1，Akt2和Akt3的IC50分别为58 nM，210 nM和2.12 µM）。据报道抑制作用具有普列克底物蛋白同源物（PH）域依赖性。即使在50 µM的高浓度情况下，它也不会对缺乏PH结构域的Akt或其他紧密相关的AGC家族激酶，PKA，PKC和SGK表现出任何抑制作用。克服了Akt1/Akt2介导的肿瘤细胞对化学疗法的抗性并显示出在体外培养的细胞和体内小鼠中均能阻断Akt1/Akt2的基础和刺激的磷酸化/激活。
一种可渗透细胞且可逆的喹喔啉化合物，可有效选择性地抑制Akt1/Akt2活性（在体外激酶测定中，Akt1，Akt2和Akt3的IC50分别为58 nM，210 nM和2.12 µM）。抑制作用似乎具有普列克底物蛋白同源物（PH）域依赖性。即使在50 µM的高浓度情况下，它也不会对缺乏PH结构域的Akt或其他紧密相关的AGC家族激酶，PKA，PKC和SGK表现出任何抑制作用。克服了Akt1/Akt2介导的肿瘤细胞对化学疗法的抗性并显示出在体外培养的细胞和体内小鼠中均能阻断Akt1/Akt2的基础和刺激的磷酸化/激活。也可获得10 mM（1 mg/181 µl）Akt抑制剂VIII，同工酶选择性，Akti-1/2（目录号124017）在DMSO中的溶液。
生化／生理作用
主要靶标
Akt1, Akt2, Akt3
Akt1, Akt2, Akt3
产物不与ATP竞争。
可逆性：是
细胞可渗透性：是
靶标IC50：在体外激酶测定中，Akt1，Akt2和Akt3分别为58 nM，210 nM和2.12 µM
包裝
用惰性气体包装
警告
毒性：标准处理（A）
重構
在复溶后，分装并冷冻保存（-70°C）。储备液可在-70°C最长稳定6个月。
其他說明
Calleja, V., et al. 2009.PLoS Biol.7, e17.
Logie, L., et al. 2007.Diabetes56, 228.
Barnett, S.F., et al. 2005.Biochem.J.385, 399.
DeFeo-Jones, D., et al. 2005.Mol.Cancer Ther.4, 271.
Zhao, Z., et al. 2005.Bioorg.Med. Chem. Lett.15, 905.
Lindsley, C.W., et al. 2005.Bioorg.Med. Chem. Lett.15, 761.
Logie, L., et al. 2007.Diabetes56, 228.
Barnett, S.F., et al. 2005.Biochem.J.385, 399.
DeFeo-Jones, D., et al. 2005.Mol.Cancer Ther.4, 271.
Zhao, Z., et al. 2005.Bioorg.Med. Chem. Lett.15, 905.
Lindsley, C.W., et al. 2005.Bioorg.Med. Chem. Lett.15, 761.
法律資訊
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。
客戶也查看了
![PERK抑制剂I，GSK2606414 GSK2606414 is a cell-permeable, highly potent inhibitor of EIF2AK3/PERK (IC₅₀ = 0.4 nM; [ATP] = 5 µM). Targets PERK in its inactive DFG conformation at the ATP-binding region.](/deepweb/assets/sigmaaldrich/product/structures/180/559/efa716dc-d5fe-4339-a6f0-0103084fc04a/640/efa716dc-d5fe-4339-a6f0-0103084fc04a.png)
Gabriel Luta et al.
International journal of molecular sciences, 22(8) (2021-05-01)
In the latest years, there has been an increased interest in nanomaterials that may provide promising novel approaches to disease diagnostics and therapeutics. Our previous results demonstrated that Carbon-dots prepared from N-hydroxyphthalimide (CD-NHF) exhibited anti-tumoral activity on several cancer cell
Lilija Wehling et al.
eLife, 11 (2022-10-19)
The Hippo signaling pathway controls cell proliferation and tissue regeneration via its transcriptional effectors yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ). The canonical pathway topology is characterized by sequential phosphorylation of kinases in the cytoplasm that defines
Jianbin Su et al.
Frontiers in pharmacology, 13, 857081-857081 (2022-04-05)
Microglia are key components of the central innate immune system. The over-activation of microglia, which occurs in nervous system disorders, is usually accompanied with retractions of their ramified processes. Reversing of microglial process retraction is a potential strategy for the
M L Brown Lobbins et al.
Clinical and experimental immunology, 191(1), 84-95 (2017-09-09)
Peripheral blood mononuclear cells taken from patients with scleroderma express increased levels of interleukin (IL)-13. Moreover, the expression of matrix metalloproteinase-1 (MMP-1) from involved scleroderma skin fibroblasts is refractory to stimulation by tumour necrosis factor (TNF)-α. To elucidate the mechanism(s)
Giacomo Della Verde et al.
Life science alliance, 5(3) (2021-12-15)
Fms-like tyrosine kinase 3 (Flt3) is a regulator of hematopoietic progenitor cells and a target of tyrosine kinase inhibitors. Flt3-targeting tyrosine kinase inhibitors can have cardiovascular side effects. Flt3 and its ligand (Flt3L) are expressed in the heart, but little
Active Filters
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務
